UK Markets closed

Defence Therapeutics Inc. (DTCFF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
5.14-0.06 (-1.15%)
At close: 10:43AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.20
Open5.14
BidN/A x N/A
AskN/A x N/A
Day's range5.14 - 5.14
52-week range2.50 - 6.41
Volume140
Avg. volume333
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

    DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous13.10.2021 / 08:30 The issuer is solely responsible for the content of this announcement.CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASEDEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCERVancouver, BC, Canada, October 13th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vac

  • EQS Group

    Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

    DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous06.10.2021 / 08:30 The issuer is solely responsible for the content of this announcement.CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASEDEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMAVancouver, BC, Canada, October 6th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is fina

  • EQS Group

    DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

    DGAP-News: Defence Therapeutics Inc. / Key word(s): Study29.09.2021 / 08:30 The issuer is solely responsible for the content of this announcement._________________________________________________________________CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASEDEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCERVancouver, BC, Canada, September 29th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology Company working on cancer ther